Saama Technologies, Inc., the number one AI clinical analytics platform company, announced today that it signed an agreement with Pfizer Inc. to develop and deploy an AI-powered analytics solution to reduce the challenges commonly experienced by clinical study data managers and monitors. Under this agreement, Saama’s award-winning Life Science Analytics Cloud (LSAC) platform will aggregate, transform, analyze, model and predict clinical data queries using deep learning techniques. Pfizer will provide the required ground truth clinical data and domain expertise to train Saama models to achieve the required accuracy.
“Saama is pioneering transformational changes to the way clinical study data is managed and understood by pharma, since current processes and systems are mostly manual and take a significant amount of time,” said Sagar Anisingaraju, Chief Strategy Officer, Saama Technologies. “As part of this collaboration with Pfizer, the deep learning models of LSAC will be further trained and improved to provide augmented intelligence, empowering data managers to operate more efficiently and effectively. Saama appreciates the leadership role that Pfizer is taking to solve this industry-wide problem by providing valuable clinical data across therapeutic areas for training our smart data query solution.”
“Historically, our industry has been limited to manual, inefficient data review processes to validate data from our clinical trials,” said Demetris Zambas, Pfizer Vice President and Head of Data Monitoring and Management. “Through our strategic collaboration with Saama Technologies, we’ve identified efficiencies to improve processes and experiences for our clinical research partners.”
About LSAC
Life Science Analytics Cloud (LSAC) is the leading AI-powered clinical analytics platform that seamlessly integrates, curates, and animates clinical trial data, delivering more actionable insights.
About Saama Technologies, Inc.
Saama is the number one AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Ten of the top 20 pharmaceutical companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at www.saama.com and follow Saama @SaamaTechInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005688/en/